TL;DR: Conditional approval is an authorization for a qualifying regenerative medicine product after review, with continuing obligations attached. T-RMAT is a separate guidance program with its own eligibility and selection conditions. Completing Phase II does not automatically produce authorization, and overseas clinical data does not automatically establish T-RMAT eligibility.

While evaluating a cross-border cell-therapy collaboration, I once considered conditional approval and T-RMAT together. After rereading the official documents, the distinctions that most needed clarification were these: being eligible to apply for a type of authorization, being accepted into guidance, receiving authorization, and a patient’s actual access to treatment are different questions.

This article organizes the public framework. It does not determine that any unnamed product qualifies, and it does not turn an earlier collaboration assessment into a case of proven efficacy or successful market entry. The discussion is limited to the statutes and TFDA documents obtained for this revision. Individual cases remain subject to the applicable rules and formal review.

First Separate the Product, Conditional Approval, and the Guidance Program

Articles 3 and 4 of the Regenerative Medicine Products Act govern products for human use that contain genes, cells, or their derivatives and define product categories. Not every medical technique described as cell therapy belongs automatically to the same product-authorization pathway.

Conditional approval under Articles 6 and 9 is an authorization decision by the competent authority for a product that meets the applicable conditions. T-RMAT is a guidance program operated by the TFDA and the Center for Drug Evaluation. Entry into the program depends separately on application eligibility and selection.

Eligibility for guidance is not marketing authorization.

The Act’s official legislative history records that it was promulgated on June 19, 2024 and took effect on January 1, 2026. The T-RMAT web page was published on March 6, 2026, while its attached program document is dated March 4. The conditional-approval application-guidance page was published on March 5, while its document is dated February 3. A web-page date and a document date should be read separately.

Conditional Approval: Completing Phase II Is Only One Condition

Under Article 9, the relevant circumstances include treatment of a life-threatening or severely disabling disease, completion of a Phase II clinical trial, and a risk-benefit review finding safety and preliminary efficacy. Article 6 additionally requires deliberation and approval by the Regenerative Medicine Review Council before conditional approval can be granted.

Completing Phase II does not automatically produce conditional approval.

The TFDA’s application guidance further explains the disease scope, submission material, and considerations. Preliminary efficacy still needs to be evaluated in relation to the product, indication, trial, and risk-benefit profile. The name of a trial phase is not proof that efficacy has been established for every use.

Conditional approval is valid for no more than five years and cannot be extended after expiry. It is different from the separately regulated drug license and should not be described as the same certificate that can simply continue to be renewed.

T-RMAT: Domestic Research and Manufacturing Eligibility Cannot Be Omitted

Section II of the TFDA’s T-RMAT program document describes the general guidance targets and priority cases. Section V separately specifies application eligibility. The two sections need to be read together.

Section V includes regenerative medicine products researched and manufactured domestically, with clinical trials conducted in Taiwan and a subject population consistent with the claimed indication. Priority may be given to products with preliminary Phase II results showing major breakthrough improvement or an ongoing Phase III trial. Domestically researched and manufactured extracellular-vesicle cases separately include priority for completion of GLP toxicology studies.

Overseas Phase II data cannot be treated as automatic eligibility for T-RMAT.

The priority periods and case types in Section II are not independent alternatives that bypass Section V. After meeting the basic conditions, an applicant still needs to submit an application and pass selection based on feasibility, clinical need, development timeline, data, and other considerations before formal admission.

Another distinction is easy to miss. T-RMAT’s priority condition referring to preliminary Phase II results is not the same as the conditional-approval requirement to have completed a Phase II clinical trial. The conditions of the two procedures cannot be substituted for one another.

Where the 15- and 120-Day Periods Begin

Section VI, item 7 of the T-RMAT document lists in-principle review periods of 15 days for a clinical-trial application and 120 days for marketing authorization, including conditional approval. The prerequisites include receiving guidance under the program, obtaining a guidance-completion certificate, and submitting a declaration that the technical dossier is exactly the same version reviewed during guidance before filing the corresponding application.

The review periods are not a guarantee of the total time from first consultation to approval.

Meetings are held in principle every two weeks and may be adjusted to the case’s progress. Rolling review and written comments are provided as needed. The document’s description of the binding effect of guidance conclusions is also conditional on the law remaining unchanged and the application remaining consistent with the material reviewed during guidance. It should not be read as a guarantee of final authorization.

For cross-border planning, the product’s eligibility, usable data, and remaining gaps need to be identified before discussing timelines. The numbers 15 or 120 should not be placed into a plan as the market-entry date every case will achieve.

Verification, Charges, and Patient Relief After Authorization

Article 10 requires an efficacy-verification trial and submission of reports periodically or within a designated period. Attached conditions also address charges and collection methods, patient-relief measures for specified serious adverse reactions, and other matters designated by the competent authority. The TFDA application guidance requires an efficacy-verification trial protocol and subsequent performance and reporting.

Post-approval verification remains an obligation; it cannot simply be treated as optional.

The original article presented efficacy-verification trials and real-world-data research as a universal either-or choice. The documents obtained for this revision do not support that generalization. Whether particular data can be accepted and how it may be used within an approved plan need separate confirmation. It cannot be used to omit statutory obligations.

After the attached conditions are fulfilled, the applicant must still file a separate registration application and receive approval before obtaining a drug license. Conditional approval does not automatically convert into full approval. If the attached conditions are not fulfilled or a major safety concern arises, the competent authority may revoke the conditional approval.

Manufacturing, distribution, safety monitoring, and source-and-destination records have their own requirements. Article 19 also distinguishes relief systems: a conditionally approved product follows the relief measures in its attached conditions, while a product with a drug license falls under the Drug Injury Relief Act. They should not be described as one identical relief mechanism.

Four-panel comic: Eligibility for guidance is not marketing authorization. Completing Phase II does not automatically produce conditional approval. Overseas Phase II data cannot be treated as automatic eligibility for T-RMAT. The review periods are not a guarantee of the total time from first consultation to approval. Post-approval verification remains an obligation; it cannot simply be treated as optional. Statutory authorization, guidance arrangements, and actual access to treatment are different questions.

For Cross-Border Collaboration, Check Each Condition Before Discussing the Opportunity

I still believe these frameworks deserve careful attention from collaboration teams. The reason is that their conditions and procedures warrant study, not that Taiwan has already caught up with every other country or that East Asian data is inherently easier to accept.

Statutory authorization, guidance arrangements, and actual access to treatment are different questions.

Different countries’ designations, scientific advice, and marketing authorizations have different legal effects. Similar language about acceleration does not make them equivalent. This article does not use unverified international application statistics or timeline rankings to support a Taiwan pathway for a particular product.

Patients also need distinctions among the authorized scope, medical arrangement, charges, and reimbursement. Collaboration teams should first organize the product classification, research and manufacturing locations, clinical data, indication, application eligibility, and subsequent obligations, then confirm unresolved questions with the competent authority. A Phase II label alone does not establish that the product can be marketed.

Further reading: A Multilingual Entry Point for NHI Data and Catastrophic Illness Certificate Validity and Reimbursement. Data lookup, certification and reimbursement, and product authorization each have different scopes. Placing them in one series does not make one automatically establish another.

Sources and revision: This article relies on the Regenerative Medicine Products Act, the TFDA conditional-approval application-guidance PDF, and the T-RMAT document linked above. The materials were checked on November 5, 2026. This revision corrects the omission of domestic research and manufacturing eligibility, the prerequisites behind the review periods, and the claim that RWD could generally substitute for the required verification trial. It does not determine the eligibility or efficacy of any individual product or a patient’s treatment choice.